



Acrux Limited (ACR:ASX)

ASX Announcement



14 August 2026

Investor Webinar Invite

Melbourne, Australia; 14 August 2026: Acrux Limited (ASX:ACR) (“Acrux” or “the Company”) is pleased to announce that it will be holding an investor webinar on Monday 17 August 2026 at 11.00AM AEST.

The webinar will be presented by Acrux’s CEO & Managing Director, John Warmbrunn.

In his webinar presentation, Mr Warmbrunn will update the market on the Company’s progress in executing its development strategy, the core of which is to improve women’s health through hormone replacement therapies.

He will specifically focus on:

- Progress in delivering the clinical and commercial milestones for Acrux’s Female Testosterone MDTs treatment
- The significance of the recently received FDA Post end-of-Phase-II response for the Female Testosterone treatment ahead of its pending Phase III trial
- A progress update on the Australian licensing agreement with Gedeon Richter Plc for Menopause Hormone Therapy (MHT) product Lenzetto®
- The continued growth in addressable markets for Female Testosterone and other already available Acrux-developed treatments.

Both Acrux shareholders and interested investors are invited to attend the webinar and participate in the accompanying Q&A session.

Acrux Limited Investor Webinar Registration Details:

DATE: Monday 17 August 2026

TIME: 11.00AM AEST

FORMAT: Zoom

Please note: Registration is required to attend this Zoom format investor webinar.

Please register in advance for the Zoom webinar using the following link:

https://us02web.zoom.us/webinar/register/WN_0lliNjy9SYyl2CBhIZzsgA

After registering, you will receive a confirmation email containing information about joining the webinar.

Questions can be submitted in advance of the webinar to Julia Maguire of The Capital Network via the following email address: julia@thecapitalnetwork.com.au

A replay of the webinar will be available on Acrux's website.

Authorised for release by the Board of Acrux Limited.

For more information, please contact:

John Warmbrunn

CEO & Managing Director

P: + 61 3 8379 0100

E: john.warmbrunn@acrux.com.au

Joanna Johnson

CFO & Company Secretary

P: + 61 3 8379 0100

E: joanna.johnson@acrux.com.au

Media Relations

Julia Maguire

The Capital Network

P: + 61 2 7257 7338

E: julia@thecapitalnetwork.com.au

About Acrux:

Acrux Limited (ASX:ACR) is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States.

[Click here to sign up to our InvestorHub](#) and keep up to date with company news and latest developments or for further information on Acrux Limited visit www.acrux.com.au

END.